Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.830
+0.040 (2.23%)
At close: Dec 20, 2024, 4:00 PM
1.880
+0.050 (2.72%)
After-hours: Dec 20, 2024, 7:03 PM EST
Akebia Therapeutics Employees
Akebia Therapeutics had 167 employees as of December 31, 2023. The number of employees decreased by 38 or -18.54% compared to the previous year.
Employees
167
Change (1Y)
-38
Growth (1Y)
-18.54%
Revenue / Employee
$1,017,240
Profits / Employee
-$275,401
Market Cap
399.27M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Community Health Systems | 61,000 |
Enhabit | 10,800 |
National Research | 435 |
Allogene Therapeutics | 233 |
Alpha Teknova | 211 |
Arcturus Therapeutics Holdings | 180 |
Nano-X Imaging | 164 |
KalVista Pharmaceuticals | 150 |
AKBA News
- 3 days ago - Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 18 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 18 days ago - U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - PRNewsWire
- 26 days ago - Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - PRNewsWire
- 4 weeks ago - Q3 2024 Earnings: Hold Akebia Therapeutics - Seeking Alpha
- 5 weeks ago - Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - PRNewsWire
- 5 weeks ago - Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - PRNewsWire
- 6 weeks ago - Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript - Seeking Alpha